National Cancer Institute; Notice of Closed Meeting, 50163 [2023-16277]
Download as PDF
<![CDATA[
50163
Federal Register / Vol. 88, No. 146 / Tuesday, August 1, 2023 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondent
Individuals, Households, Private Sector, State
Government, Local Government, Tribal Government,
or Federal Government.
Totals .......................................................................
Dated: July 27, 2023.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2023–16315 Filed 7–31–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
VerDate Sep<11>2014
18:34 Jul 31, 2023
Jkt 259001
Number of
respondents
Form name
Average
burden per
response
(in hours)
Total burden
hour
Performance
Measurement.
500
1
30/60
250
Program Monitoring.
Program Evaluations.
Grantee Effectiveness.
Resource Management.
Feedback ............
Forms ..................
500
1
15/60
125
500
1
45/60
375
1,000
1
15/60
250
500
1
10/60
83
5,000
3,000
1
1
15/60
30/60
1,250
1,500
........................
11,000
........................
3,833
.............................
Name of Committee: National Cancer
Institute Special Emphasis Panel; June 2023
Cycle 44 NExT SEP Committee Meeting.
Date: August 17, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, Maryland 20852 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, Maryland
20817, 301–496–4291, mroczkoskib@
mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, Maryland 20850, 240–276–5683,
toby.hecht2@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 27, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–16277 Filed 7–31–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Number of
responses per
respondent
Frm 00065
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the President’s Cancer Panel.
The meeting will be held as a virtual
meeting and open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting can be
accessed by clicking on the following
link: https://nci.rev.vbrick.com/#/
webcasts/presidentscancerpanel.
Name of Committee: President’s Cancer
Panel.
Date: September 7, 2023.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: President’s Cancer Panel National
Cancer Plan Stakeholder Meeting.
Place: National Institutes of Health, 31
Center Drive, Building 31, Room 11A48,
Rockville, MD 20850 (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH 31,
Center Drive, Room 11A48, MSC 2590,
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
E:\FR\FM\01AUN1.SGM
01AUN1
]]>Agencies
[Federal Register Volume 88, Number 146 (Tuesday, August 1, 2023)]
[Notices]
[Page 50163]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-16277]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; June 2023 Cycle 44 NExT SEP Committee Meeting.
Date: August 17, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Room 3A44, Bethesda, Maryland 20852 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski, Ph.D., Executive
Secretary, Discovery Experimental Therapeutics Program, National
Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda,
Maryland 20817, 301-496-4291, [email protected].
Toby Hecht, Ph.D., Executive Secretary, Development Experimental
Therapeutics Program, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 3W110, Rockville, Maryland 20850, 240-276-5683,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 27, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-16277 Filed 7-31-23; 8:45 am]
BILLING CODE 4140-01-P
